MTIP
HTGM

Magee Thomson Investment Partners’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Magee Thomson Investment Partners’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2
Closed -$4K – 116
2015
Q2 		$4K Buy
+2
New +$5.11K ﹤0.01% 94

Other funds holding HTGM

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Magee Thomson Investment Partners's HTGM Position: Q3 2015 in Review

Magee Thomson Investment Partners sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2015, closing a stake of 2 shares — an estimated $4K sold.

Magee Thomson Investment Partners first reported a position in HTGM in Q2 2015 and held it in 1 quarter. The position peaked at $4K in Q2 2015. 21 funds tracked by Wall St. Rank hold HTGM as of Q3 2015.

  • Magee Thomson Investment Partners reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 2 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2015, an estimated $4K.
  • Magee Thomson Investment Partners first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Magee Thomson Investment Partners's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $4K in Q2 2015.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2015.

Based on Magee Thomson Investment Partners's 13F filing for Q3 2015, filed 26 Oct 2015.